TABLE 6.

The diagnostic performance of the DNA sequencing-based method in comparison with drug susceptibility testinga

Drug susceptibility test resultbNo. of isolates (n = 138)% Sensitivityc% Specificityd% Test efficiencye
Mutation positiveMutation negative
RIF
    Resistant280100100100
    Susceptible0110
INH
    Resistant34489.510097.1
    Susceptible0100
EMB
    Resistant15383.310097.8
    Susceptible0120
PZA
    Resistant170100100100
    Susceptible0121
STR
    Resistant181260.010091.3
    Susceptible0108
OFX
    Resistant30100100100
    Susceptible0135
  • a The diagnostic performance of the DNA sequencing-based method in comparison with drug susceptibility testing was determined after resolution of polymorphisms.

  • b Drug susceptibility for antituberculosis agents except for PZA was determined by the agar proportion method according to NCCLS (now CLSI) guidelines, and that for PZA was determined by PZase activity.

  • c Sensitivity: no. of drug-resistant isolates with mutations/(no. of drug-resistant isolates with mutations + no. of drug-resistant isolates without mutations).

  • d Specificity: no. of drug-susceptible isolates without mutations/(no. of drug-susceptible isolates with mutations + no. of drug-susceptible isolates without mutations).

  • e Test efficiency: (no. of drug-resistant isolates with mutations + no. of drug-susceptible isolates without mutations)/no. of all isolates tested.